Peptide questions · Dulaglutide
Dulaglutide side effects: what studies and users report
Reviewed Evidence: EstablishedPublished by PepVault
The side effects most commonly reported for dulaglutide are nausea, diarrhea and vomiting, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Its safety note opens: The Trulicity label carries the GLP-1 class boxed warning: dulaglutide caused thyroid C-cell tumors in rats given it for a lifetime, and whether it does so in people is not known, so the label rules it out for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2.
What is commonly reported with dulaglutide
- Nausea
- Diarrhea
- Vomiting
- Abdominal pain
- Decreased appetite
- Indigestion
- Fatigue
Common here means the library lists it among the effects people most often report; the list doesn’t say how often each one happens.
| Effect | Also listed for (of 24) |
|---|---|
| Nausea | 21: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 17 more |
| Diarrhea | 20: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 16 more |
| Vomiting | 18: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 14 more |
| Abdominal pain | 7: Semaglutide (oral), Tirzepatide, Retatrutide, Setmelanotide and 3 more |
| Decreased appetite | 9: Semaglutide, Semaglutide (oral), Tirzepatide, Retatrutide and 5 more |
| Indigestion | 2: Exenatide, Orforglipron |
| Fatigue | 7: Semaglutide, Tirzepatide, Retatrutide, Survodutide and 3 more |

Model. Individual results vary.
Which dulaglutide side effects the metabolic & GLP-1 group shares
Across the 25 metabolic & GLP-1 compounds in the library, the effects listed most often are nausea (22 of 25), diarrhea (21 of 25), vomiting (19 of 25) and constipation (14 of 25). Every effect on dulaglutide’s list also appears for at least one other metabolic & GLP-1 compound, so nothing on it is dulaglutide’s own.
What the dulaglutide safety notes say
The library’s safety note
The Trulicity label carries the GLP-1 class boxed warning: dulaglutide caused thyroid C-cell tumors in rats given it for a lifetime, and whether it does so in people is not known, so the label rules it out for anyone with a personal or family history of medullary thyroid carcinoma or MEN 2. Its other warnings are acute pancreatitis (confirmed in 0.2% on 1.5 mg, 0.3% on 3 mg and 0.5% on 4.5 mg in the high-dose trial), low blood sugar when combined with insulin or a sulfonylurea, serious allergic reactions, kidney injury from dehydration after vomiting or diarrhea, severe stomach problems, a temporary worsening of diabetic retinopathy when glucose improves quickly, gallbladder disease, and food reaching the lungs under anesthesia. In the placebo-controlled trials, GI side effects affected 32% on 0.75 mg and 41% on 1.5 mg vs 21% on placebo, mostly mild or moderate, and resting heart rate rose 2 to 4 beats per minute on average. These are label findings; review them with your clinician.
The library’s interaction note
Dulaglutide slows stomach emptying, most after the first dose, which can slow the absorption of oral medicines: at 1.5 mg it did not change the absorption of the oral drugs tested to a clinically relevant degree, there is little data at 3 and 4.5 mg, and the label suggests monitoring narrow-margin drugs such as warfarin. With insulin or a sulfonylurea, the label suggests considering lower doses of those to limit low blood sugar. It is a GLP-1 drug itself, so it is not stacked with another one. Discuss all your medicines with your clinician.
These are reference notes from published research and reported use, not advice for a person: discuss your own situation with your clinician.
Where the dulaglutide reports come from
The library rates the evidence on dulaglutide as established: clinical trials or FDA-approved use exist.
Of the library’s 7 research notes on dulaglutide, 6 rest on randomized trials and 1 on community reports.
Our 10 study pages on dulaglutide: 2 animal studies (mice), 7 randomized trials and 1 clinical trial.
So dulaglutide has controlled trials in people to set its listed effects against.
What our dulaglutide study pages report on safety
Dulaglutide: switching to tirzepatide beat dose escalation on HbA1c
Randomized trial, human, 2025: At week 40, HbA1c dropped by 1.44% in the tirzepatide arm (15 mg or the highest tolerated dose) and by 0.67% in the dulaglutide arm (4.5 mg or the highest tolerated dose), an estimated difference of -0.77%. Serious side effects happened in 10 (7.2%) people on tirzepatide and 10 (7.0%) on dulaglutide.
Dulaglutide cut HbA1c 1.3 vs 2.4 to 2.8 with tirzepatide at 52 weeks
Randomized trial, human, 2022: Nausea affected 8% of the dulaglutide group and 12% to 20% of the tirzepatide groups; constipation affected 11% versus 14% to 18%. In this Japanese trial, dulaglutide 0.75 mg lowered blood sugar but did little to body weight, and tirzepatide lowered both more, with more nausea.
Dulaglutide lowered major cardiovascular events (HR 0.88) in REWIND
Randomized trial, human, 2019: Gut side effects were more common on dulaglutide, reported by 2347 people (47.4%) versus 1687 (34.1%) on placebo. In a large, long trial of older adults with type 2 diabetes, dulaglutide led to fewer major cardiovascular events than placebo, but gut side effects were more common and overall deaths did not clearly differ.
Dulaglutide cut HbA1c and weight less than semaglutide in SUSTAIN 7
Randomized trial, human, 2018: Gut-related side effects were the most common problem: 33% of the dulaglutide 0.75 mg arm and 48% of the dulaglutide 1.5 mg arm, against 43% and 44% with semaglutide, and they were the top reason people stopped either drug. In this head-to-head trial, dulaglutide lowered blood sugar and weight, but less than semaglutide at both dose levels compared, with gut side effects common on both.
Questions people ask
What are the side effects of dulaglutide?
The side effects most commonly reported for dulaglutide are nausea, diarrhea and vomiting, among 7 the library lists; the library’s evidence on it includes controlled trials in people.
Do dulaglutide’s side effects come from human studies?
The library rates the evidence on dulaglutide as established, and the library’s evidence on it includes controlled trials in people.
Which dulaglutide side effects are its own?
None: each effect the library lists for dulaglutide is listed for at least one other metabolic & GLP-1 compound too.
Does dulaglutide interact with other medicines?
The library’s interaction note on dulaglutide begins: dulaglutide slows stomach emptying, most after the first dose, which can slow the absorption of oral medicines: at 1.5 mg it did not change the absorption of the oral drugs tested to a clinically relevant degree, there is little data at 3 and 4.5 mg, and the label suggests monitoring narrow-margin drugs such as warfarin.